Details

Autor(en) / Beteiligte

• Chen, Ping
• Zhang, Xu
• Ding, Renbo
• Yang, Linglin
• Lyu, Xueying
• Zeng, Jianming
• Lei, Josh Haipeng
• Wang, Lijian
• Bi, Jiong
• Shao, Nan
• Shu, Ditian
• Wu, Bin
• Wu, Jingbo
• Yang, Zhihui
• Wang, Haiyan
• Wang, Biqiong
• Xiong, Kang
• Lu, Yun
• Fu, Shaozhi
• Choi, Tak Kan
• Lon, Ng Wai
• Zhang, Aiping
• Tang, Dongyang
• Quan, Yingyao
• Meng, Ya
• Miao, Kai
• Sun, Heng
• Zhao, Ming
• Bao, Jiaolin
• Zhang, Lei
• Xu, Xiaoling
• Shi, Yanxia
• Lin, Ying
• Deng, Chuxia

Titel

Patient‐Derived Organoids Can Guide Personalized‐Therapies for Patients with Advanced Breast Cancer

Ist Teil von

• Advanced science, 2021-11, Vol.8 (22), p.e2101176-n/a

Ort / Verlag

Germany: John Wiley & Sons, Inc

Erscheinungsjahr

2021

Link zum Volltext

Quelle

Wiley Blackwell Single Titles

Beschreibungen/Notizen

• Most breast cancers at an advanced stage exhibit an aggressive nature, and there is a lack of effective anticancer options. Herein, the development of patient‐derived organoids (PDOs) is described as a real‐time platform to explore the feasibility of tailored treatment for refractory breast cancers. PDOs are successfully generated from breast cancer tissues, including heavily treated specimens. The microtubule‐targeting drug‐sensitive response signatures of PDOs predict improved distant relapse‐free survival for invasive breast cancers treated with adjuvant chemotherapy. It is further demonstrated that PDO pharmaco‐phenotyping reflects the previous treatment responses of the corresponding patients. Finally, as clinical case studies, all patients who receive at least one drug predicate to be sensitive by PDOs achieve good responses. Altogether, the PDO model is developed as an effective platform for evaluating patient‐specific drug sensitivity in vitro, which can guide personal treatment decisions for breast cancer patients at terminal stage. Personalized therapies are urgently needed for patients with advanced breast cancers. Patient‐derived organoids (PDOs) can be generated from breast cancer tissues for the identification of anticancer drugs with high efficacy. PDO pharmaco‐phenotyping can not only reflect the previous treatment responses of patients, but also serve as an in‐time platform to guide tailored therapy for the refractory disease.